Abstract
The embryonic phenotype transformation of cardiomyocytes is an important characteristic of pathological cardiac hypertrophy. It includes transcriptional reprogramming of gene expression, a switch from lipid metabolism to carbohydrate metabolism, and a shift from α-myosin heavy chain (MHC) to fetal ß-MHC expression. The embryonic and adult cardiacmyocytes have distinct gene expression profiles. A series of genes that are expressed in embryos are later shut down after birth through the inhibition of endogenous constitutively activated molecules. These genes can be reactivated if these inhibitors are inactivated or downregulated, as occurs under certain pathological conditions. This promotes pathological cardiac hypertrophy. In this review, we list a class of endogenous molecules whose expression is inactivated during cardiac hypertrophy. They play a positive role in inhibition of the occurrence and development of cardiac hypertrophy and constitute the first natural line of defense against pathological cardiac hypertrophy.
Keywords: Cardiac hypertrophy, expression, first line of defense, inhibitors
Current Molecular Medicine
Title:The First Line of Defense Against Cardiac Hypertrophy
Volume: 13 Issue: 4
Author(s): X. Fan and X. Wu
Affiliation:
Keywords: Cardiac hypertrophy, expression, first line of defense, inhibitors
Abstract: The embryonic phenotype transformation of cardiomyocytes is an important characteristic of pathological cardiac hypertrophy. It includes transcriptional reprogramming of gene expression, a switch from lipid metabolism to carbohydrate metabolism, and a shift from α-myosin heavy chain (MHC) to fetal ß-MHC expression. The embryonic and adult cardiacmyocytes have distinct gene expression profiles. A series of genes that are expressed in embryos are later shut down after birth through the inhibition of endogenous constitutively activated molecules. These genes can be reactivated if these inhibitors are inactivated or downregulated, as occurs under certain pathological conditions. This promotes pathological cardiac hypertrophy. In this review, we list a class of endogenous molecules whose expression is inactivated during cardiac hypertrophy. They play a positive role in inhibition of the occurrence and development of cardiac hypertrophy and constitute the first natural line of defense against pathological cardiac hypertrophy.
Export Options
About this article
Cite this article as:
Fan X. and Wu X., The First Line of Defense Against Cardiac Hypertrophy, Current Molecular Medicine 2013; 13 (4) . https://dx.doi.org/10.2174/1566524011313040015
DOI https://dx.doi.org/10.2174/1566524011313040015 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Actionable Nutrigenetics for Genetically Based Diseases? A New Critical Path to P4 Medicine
Current Pharmacogenomics and Personalized Medicine Redox Control of Cardiovascular Homeostasis by Angiotensin II
Current Pharmaceutical Design Common Genetic Conditions of Ischemic Stroke to Keep in Mind
Current Molecular Medicine Stairway to Heaven or Hell? Perspectives and Limitations of Chagas Disease Chemotherapy
Current Topics in Medicinal Chemistry Mesenchymal Stem Cells: Promising for Myocardial Regeneration?
Current Stem Cell Research & Therapy Editorial: Modifying Cardiovascular Risk Factors: Acquired Topics and Emerging Concepts
Current Pharmaceutical Design Persistent Pulmonary Hypertension of the Newborn: Physiology, Hemodynamic Assessment and Novel Therapies
Current Pediatric Reviews Cellular Strategies to Combat Protein Misfolding: Intricate Role of Hsp70 in Stress Management
Current Chemical Biology Cystatin C: An Emerging Biomarker in Cardiovascular Disease
Current Topics in Medicinal Chemistry HER-2 Signaling and Inhibition in Breast Cancer
Current Cancer Drug Targets Endothelial Dysfunction in Morbid Obesity
Current Pharmaceutical Design Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System
Current Diabetes Reviews Phytochemical Therapies in Vascular Functioning: A Molecular Approach
Current Vascular Pharmacology Trends in Mitochondrial Therapeutics for Neurological Disease
Current Medicinal Chemistry Management of Antineutrophil Cytoplasmic Antibody Associated Vasculitis
Current Immunology Reviews (Discontinued) Impact of Matrix Metalloproteinases on Atherosclerosis
Current Drug Targets COVID-19: The Significance of Platelets, Mitochondria, Vitamin D, Serotonin and the Gut Microbiota
Current Medicinal Chemistry The Role of Stem Cells in Muscular Dystrophies
Current Gene Therapy Angiotensin-Converting Enzyme Inhibitors: Mechanisms of Action and Implications In Anesthesia Practice
Current Pharmaceutical Design A Brief History of ‘Lone’ Atrial Fibrillation: From ‘A Peculiar Pulse Irregularity’ to a Modern Public Health Concern
Current Pharmaceutical Design